Issued 2026-08-13 at $134.55 · now $134.45 (2026-08-13, −0.1% since)
Based on its own history, a month from the 2026-08-13 close, APGE has typically landed between $102.70 and $192.39 — a range of −23.7% to +43.0% from the issuance price $134.55.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
753 overlapping 1 month windows · 2023-07-14 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($134.55) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where APGE has typically landed a month from the 2026-08-13 close of $134.55 — the range is history, not a prediction.
- now $134.45 (-0.1%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $138.44 (+2.9%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $120.19–$156.68
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $102.7–$192.39
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2024-03-27 | −30.8% | −32.7% | +0.0% |
| 2024-03-26 | −30.2% | −30.2% | +3.6% |
| 2023-09-27 | −30.1% | −30.1% | +3.2% |
| 3 best | |||
| 2024-02-12 | +96.6% | −2.8% | +96.6% |
| 2024-02-27 | +95.7% | +0.0% | +100.6% |
| 2024-02-22 | +94.9% | −0.9% | +98.8% |
753 overlapping windows · 2023-07-14 – 2026-08-13 · not cherry-picked
Pending catalysts
- November 2026 — Trial primary completion: Phase 2 primary completion: A Study Evaluating APG777 in Atopic Dermatitis (source, as of 2026-08-14)
- December 2029 — Trial primary completion: Phase 2 primary completion: A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~4 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.